PFIZER
|
PFIZER Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 157.91 | 167.78 | 120.51 | 136.38 | 133.89 |
| CEPS(Rs) | 170.53 | 181.07 | 134.12 | 159.44 | 159.03 |
| DPS(Rs) | 75.00 | 165.00 | 35.00 | 70.00 | 30.00 |
| Book NAV/Share(Rs) | 918.67 | 921.84 | 785.91 | 701.05 | 626.10 |
| Tax Rate(%) | 25.96 | 24.46 | 26.10 | 24.28 | 20.74 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 34.44 | 31.01 | 27.43 | 31.60 | 30.79 |
| EBIT Margin(%) | 37.53 | 42.91 | 32.88 | 32.71 | 28.86 |
| Pre Tax Margin(%) | 37.17 | 42.56 | 32.21 | 32.18 | 28.46 |
| PAT Margin (%) | 27.52 | 32.15 | 23.81 | 24.37 | 22.56 |
| Cash Profit Margin (%) | 29.72 | 34.70 | 26.49 | 28.49 | 26.79 |
| Performance Ratios | |||||
| ROA(%) | 14.91 | 17.03 | 13.65 | 16.09 | 17.24 |
| ROE(%) | 17.16 | 19.65 | 16.21 | 20.55 | 23.30 |
| ROCE(%) | 23.39 | 26.21 | 22.37 | 27.56 | 29.78 |
| Asset Turnover(x) | 0.54 | 0.53 | 0.57 | 0.66 | 0.76 |
| Sales/Fixed Asset(x) | 1.85 | 1.72 | 1.71 | 1.90 | 2.07 |
| Working Capital/Sales(x) | 0.83 | 0.81 | 1.06 | 1.39 | 1.80 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.54 | 0.58 | 0.58 | 0.53 | 0.48 |
| Receivable days | 26.06 | 29.10 | 26.74 | 20.98 | 16.89 |
| Inventory Days | 65.95 | 69.53 | 67.09 | 61.77 | 59.41 |
| Payable days | 81.01 | 76.77 | 95.85 | 109.35 | 114.15 |
| Valuation Parameters | |||||
| PER(x) | 29.89 | 23.86 | 34.80 | 25.40 | 32.50 |
| PCE(x) | 27.68 | 22.11 | 31.27 | 21.73 | 27.36 |
| Price/Book(x) | 5.14 | 4.34 | 5.34 | 4.94 | 6.95 |
| Yield(%) | 1.59 | 4.12 | 0.83 | 2.02 | 0.69 |
| EV/Net Sales(x) | 7.34 | 6.80 | 7.82 | 5.77 | 7.00 |
| EV/Core EBITDA(x) | 16.93 | 17.01 | 21.01 | 15.37 | 20.33 |
| EV/EBIT(x) | 18.76 | 15.15 | 22.51 | 16.71 | 23.31 |
| EV/CE(x) | 4.40 | 3.68 | 4.76 | 4.36 | 4.74 |
| M Cap / Sales | 8.57 | 8.03 | 8.75 | 6.54 | 7.62 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.45 | 4.02 | -9.55 | -7.13 | 16.64 |
| Core EBITDA Growth(%) | 19.68 | 11.86 | -10.35 | 1.27 | 13.24 |
| EBIT Growth(%) | -3.84 | 34.55 | -9.07 | 6.88 | 14.54 |
| PAT Growth(%) | -5.88 | 39.23 | -11.64 | 1.86 | 23.10 |
| EPS Growth(%) | -5.88 | 39.23 | -11.64 | 1.86 | 23.10 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 6.06 | 6.17 | 5.01 | 3.79 | 2.77 |
| Quick Ratio(x) | 5.31 | 5.33 | 4.22 | 3.16 | 2.24 |
| Interest Cover(x) | 102.95 | 120.54 | 49.35 | 62.13 | 73.23 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of PFIZER
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| PFIZER | ₹20,976.1 Cr | -2.5% | 1.3% | -15.4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹470,786.0 Cr | 0.5% | 6.8% | 16.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹194,590.0 Cr | 0.6% | 8.7% | 7.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,658.0 Cr | 0.4% | 13.8% | 46.9% | Stock Analytics | |
| CIPLA | ₹115,728.0 Cr | -0.4% | 5.8% | -2.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,708.0 Cr | -1.9% | -5.1% | -2.2% | Stock Analytics | |
PFIZER Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| PFIZER | -2.5% |
1.3% |
-15.4% |
| SENSEX | 0.5% |
0.1% |
-6.1% |
You may also like the below Video Courses